{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Cancer+%28mCRPC%29", "query": { "condition": "Metastatic Castration-resistant Prostate Cancer (mCRPC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 221, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Cancer+%28mCRPC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:31:57.400Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06318273", "title": "A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "ABBV-969", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 230, "start_date": "2024-03-08", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 9, "location_summary": "Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06318273" }, { "nct_id": "NCT06033001", "title": "Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "overall_status": "TEMPORARILY_NOT_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Castration-Resistant Prostatic Cancer" ], "interventions": [ { "name": "[Lu-177]-PNT2002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lantheus Medical Imaging", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 7, "location_summary": "Newport Beach, California • Hartford, Connecticut • Jupiter, Florida + 4 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Trinity", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06033001" }, { "nct_id": "NCT06457919", "title": "A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Tinengotinib", "type": "DRUG" }, { "name": "abiraterone acetate with prednisone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2024-06-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 12, "location_summary": "New Haven, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06457919" }, { "nct_id": "NCT03792841", "title": "Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "acapatamab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Cytochrome P450 (CYP) Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 212, "start_date": "2019-02-05", "completion_date": "2023-06-29", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 13, "location_summary": "Campbell, California • Duarte, California • Long Beach, California + 9 more", "locations": [ { "city": "Campbell", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03792841" }, { "nct_id": "NCT06531499", "title": "A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "AAA617", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) analogues", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) antagonists", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 106, "start_date": "2024-11-11", "completion_date": "2028-11-24", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 5, "location_summary": "Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06531499" }, { "nct_id": "NCT02115828", "title": "A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2014-04", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2018-07-20", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115828" }, { "nct_id": "NCT02711956", "title": "A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "ZEN003694", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zenith Epigenetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 75, "start_date": "2016-12", "completion_date": "2019-11", "has_results": true, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Detroit, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711956" }, { "nct_id": "NCT02312557", "title": "Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Hormone-Resistant Prostate Cancer", "PSA Progression", "Recurrent Prostate Carcinoma", "Stage IV Prostate Adenocarcinoma Cancer AJCC v8" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 58, "start_date": "2014-11-18", "completion_date": "2026-10-31", "has_results": true, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02312557" }, { "nct_id": "NCT01977651", "title": "A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 424, "start_date": "2013-09-25", "completion_date": "2019-01-11", "has_results": true, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 9, "location_summary": "Anchorage, Alaska • Detroit, Michigan • New York, New York + 5 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01977651" }, { "nct_id": "NCT03834519", "title": "Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 793, "start_date": "2019-05-02", "completion_date": "2024-01-27", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-05-21T22:31:57.400Z", "location_count": 29, "location_summary": "Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Quincy", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03834519" } ] }